List of Excipients in Branded Drug PROCTOSOL-HC

Generic Drugs Containing PROCTOSOL-HC

Company	Ingredient	NDC	Excipient
Sun Pharmaceutical Industries Inc	hydrocortisone	10631-407	CETYL ALCOHOL
Sun Pharmaceutical Industries Inc	hydrocortisone	10631-407	ISOPROPYL PALMITATE
Sun Pharmaceutical Industries Inc	hydrocortisone	10631-407	LANOLIN OIL

What are the Most Frequently-Used Excipients in PROCTOSOL-HC?

# Of NDCs	Excipient
3	CETYL ALCOHOL
3	ISOPROPYL PALMITATE
3	LANOLIN OIL

# PROCTOSOL-HC Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Proctosol-HC is a prescription rectal cream containing hydrocortisone acetate 2.5% for the temporary relief of inflammation and itching associated with hemorrhoids and other anorectal conditions. Its commercial opportunity is primarily formulation-led. Hydrocortisone acetate is an established, low-cost corticosteroid with limited standalone exclusivity value. Competitive differentiation depends on rheology, spreadability, skin feel, preservative selection, microbiological control, packaging, patient adherence, and regulatory positioning.[1]

What is Proctosol-HC and how is it regulated?

Proctosol-HC is a topical rectal dosage form containing hydrocortisone acetate, a corticosteroid intended for local anorectal use. The product is marketed as a prescription drug in the United States.[1]

Attribute	Proctosol-HC profile
Active ingredient	Hydrocortisone acetate
Strength	2.5%
Dosage form	Rectal cream
Route	Rectal and perianal topical administration
Therapeutic class	Corticosteroid
Primary use	Relief of inflammation and itching associated with hemorrhoidal and anorectal conditions
Regulatory category	Prescription drug
Primary commercial competitors	Generic hydrocortisone acetate rectal creams, hydrocortisone suppositories, OTC hydrocortisone products, combination hemorrhoidal products
Principal differentiation lever	Vehicle and delivery performance

The product is not a biologic, so biosimilar risk is not relevant. Competition comes from generic topical and rectal products, authorized generics, alternative dosage forms, and nonprescription hemorrhoidal treatments.

What excipients are used in Proctosol-HC?

The Proctosol-HC label identifies a conventional oil-in-water rectal cream system. Listed inactive ingredients include cetyl alcohol, glyceryl monostearate, methylparaben, propylene glycol, propylparaben, purified water, stearyl alcohol, and white petrolatum.[1]

These excipients perform distinct technical functions:

Excipient category	Representative ingredients	Formulation role
Emollient and occlusive phase	White petrolatum	Reduces water loss and improves barrier feel
Fatty alcohol structuring system	Cetyl alcohol, stearyl alcohol	Builds viscosity, cream body, and emulsion stability
Emulsification and consistency	Glyceryl monostearate	Supports oil-water dispersion and texture
Humectant and cosolvent	Propylene glycol	Supports hydration and may assist drug distribution
Preservatives	Methylparaben, propylparaben	Controls microbial growth in the multidose aqueous cream
Continuous phase	Purified water	Provides the aqueous component of the emulsion

The excipient system is commercially practical but not highly differentiated. Its value lies in delivering hydrocortisone acetate in a spreadable, stable, cosmetically acceptable base rather than in creating a new pharmacologic mechanism.

Why does the vehicle matter for hydrocortisone acetate?

Hydrocortisone acetate has limited water solubility. The formulation therefore must maintain the active ingredient in a physically stable state while distributing it consistently through the cream. Particle size, wetting, mixing energy, emulsion structure, and storage conditions can affect dose uniformity and application performance.

For rectal use, the vehicle must also balance competing requirements:

• Sufficient viscosity to remain at the application site.
• Low enough yield stress for easy extrusion.
• Smooth texture without gritty particles.
• Adequate spreadability over inflamed tissue.
• Limited stinging from solvents or surfactants.
• Resistance to phase separation during storage.
• Microbiological stability after repeated opening.

A technically superior cream can create commercial value even when the active ingredient is off patent, provided the sponsor can demonstrate consistent quality and obtain a viable regulatory pathway.

What formulation patents could protect a Proctosol-HC follow-on?

The active ingredient itself offers limited patent opportunity. A follow-on product would need protection around the formulation, manufacturing process, delivery system, packaging, or clinical use.

Potential patentable subject matter includes:

Low-irritancy preservative systems

A preservative-free or low-preservative cream could target patients who experience burning, irritation, or contact sensitivity. Technical approaches include:

• Single-use foil or laminate sachets.
• Metered-dose applicators that limit microbial ingress.
• Airless pumps.
• Reduced paraben concentrations.
• Alternative preservative systems compatible with rectal tissue.

A preservative-free claim would require strong microbiological and stability data. Multidose aqueous products remain vulnerable to contamination after opening, so packaging and in-use stability would be central to the patent and regulatory package.

Bioadhesive rectal creams

Mucoadhesive polymers could increase residence time and reduce leakage. Candidates may include selected cellulose derivatives, polycarbophil, carbomers, alginates, or other pharmaceutically acceptable polymers.

The commercial challenge is balancing adhesion against patient acceptability. Excessive adhesion can make application uncomfortable and complicate cleaning. A credible patent would need defined polymer concentrations, rheological limits, adhesion testing, and evidence that the system improves local retention or symptom control.

Improved spreadability and extrusion

A formulation with controlled viscosity across a broad temperature range could address a practical weakness of conventional creams. Patent claims could focus on:

• Viscosity at specified shear rates.
• Extrusion force from a defined tube or applicator.
• Particle-size distribution of hydrocortisone acetate.
• Absence of phase separation.
• Spread area under standardized pressure.
• Stability after freeze-thaw or elevated-temperature cycling.

These claims are more defensible when linked to a measurable patient-use benefit.

Combination formulations

A sponsor could combine hydrocortisone acetate with a second active ingredient, such as a local anesthetic or protectant, subject to regulatory and clinical requirements. Potential benefits include treatment of inflammation together with pain or irritation.

Combination products face higher development and regulatory risk. The sponsor must establish compatibility, dose rationale, safety, and contribution of each active ingredient. The formulation must also avoid increasing systemic corticosteroid exposure or local adverse effects.

Applicator and delivery-system claims

The applicator may provide stronger commercial differentiation than the cream itself. Opportunities include:

• Narrow, low-trauma rectal tips.
• Rounded or flexible cannula designs.
• Dose-limiting applicators.
• Preloaded single-use applicators.
• Applicators designed for perianal rather than intrarectal application.
• Child-resistant or senior-friendly packaging.

Device claims may be pursued separately from formulation claims. A combination-product strategy could create additional barriers to direct substitution, although it may also increase manufacturing and regulatory complexity.

How strong is the excipient-based patent opportunity?

The patent opportunity is moderate for a genuinely differentiated delivery system and weak for routine substitution of one conventional excipient for another.

Strategy	Patent potential	Regulatory complexity	Commercial attractiveness
Replace one fatty alcohol with another	Low	Low	Low
Reduce or remove parabens	Moderate	Moderate	Moderate
Preservative-free single-use packaging	Moderate to high	Moderate	High
Bioadhesive cream	Moderate to high	High	Moderate to high
Controlled-release rectal formulation	High	High	Potentially high
Improved applicator	Moderate to high	Moderate to high	High
Hydrocortisone acetate combination product	Moderate	High	Moderate
Cosmetic or fragrance modification	Low	Low	Low

Routine excipient substitutions may support an abbreviated regulatory filing but usually do not create meaningful freedom-to-operate barriers. Patent strength improves when the formulation combines defined composition ranges with reproducible performance characteristics and a clinically relevant benefit.

What regulatory pathway applies to a Proctosol-HC follow-on?

A hydrocortisone acetate rectal cream follow-on may pursue an abbreviated application if the reference product and proposed product can satisfy applicable requirements for pharmaceutical equivalence, quality, and bioequivalence or other product-specific standards.

The regulatory strategy depends on the extent of change:

Product concept	Likely regulatory issue
Same strength and conventional cream	Pharmaceutical equivalence and bioequivalence requirements
Different excipient system	Comparative performance, safety, and possible clinical support
Preservative-free multidose product	In-use microbiological control and packaging validation
New applicator	Device performance and combination-product review
New indication	Method-of-use support and clinical evidence
Controlled-release product	New drug delivery performance and expanded development package
OTC repositioning	Compliance with applicable monograph or approval requirements

The FDA Inactive Ingredient Database can support excipient selection by identifying prior use in approved products and relevant route-specific precedent.[2] Prior use does not eliminate the need to justify concentration, function, safety, compatibility, and product performance.

USP standards may apply to excipient identity, purity, microbial quality, and analytical testing. The sponsor should also assess elemental impurities, residual solvents, extractables and leachables, preservative effectiveness, and microbiological quality under applicable FDA and ICH expectations.[3][4]

What FDA exclusivity and Orange Book issues affect Proctosol-HC?

Hydrocortisone acetate is an established corticosteroid, and the commercial exposure is primarily generic rather than exclusivity-driven. The key diligence questions are whether the marketed product is associated with an FDA-listed application, whether the product has active Orange Book patent listings, and whether the proposed follow-on would be subject to Paragraph IV certification.

A standard abbreviated application could encounter four patent positions:

1. No listed patents, allowing approval based on regulatory readiness.
2. Paragraph III certification, delaying approval until patent expiry.
3. Paragraph IV certification, asserting that listed patents are invalid, unenforceable, or not infringed.
4. Section viii carve-out, excluding a patented method of use from labeling.

For a conventional hydrocortisone acetate rectal cream, formulation and method-of-use patents are more commercially relevant than composition-of-matter patents. The Orange Book should be reviewed for the specific reference product and application number before investment or filing decisions.[5]

There is no biologic reference-product framework for Proctosol-HC, and biosimilar litigation does not apply.

When does Proctosol-HC lose exclusivity?

The practical answer is that market exclusivity for a conventional hydrocortisone acetate rectal cream is generally limited by the established nature of the active ingredient and the availability of generic competition. The relevant dates are product-specific:

Exclusivity issue	Commercial implication
New chemical entity exclusivity	Not expected for hydrocortisone acetate
Orphan-drug exclusivity	Not associated with the standard hemorrhoidal use
Pediatric exclusivity	Applies only if specifically granted
Listed patent expiry	Can affect an abbreviated applicant's approval or launch
Formulation patent expiry	May affect a differentiated delivery product
Method-of-use patent expiry	May require labeling restrictions or a carve-out
Regulatory exclusivity for a new formulation	Possible only if the product qualifies under the applicable FDA pathway

The product’s commercial life therefore depends more on manufacturing efficiency, channel access, pharmacy substitution, pricing, and differentiated packaging than on long-duration exclusivity.

Which companies are competing in the hydrocortisone rectal market?

Competition comes from several groups:

• Generic manufacturers of hydrocortisone acetate rectal cream.
• Branded manufacturers selling hemorrhoidal creams and suppositories.
• OTC manufacturers using hydrocortisone, phenylephrine, protectants, anesthetics, or botanical ingredients.
• Contract manufacturers supplying private-label pharmacy and online brands.
• Developers of single-use or applicator-based anorectal products.

The closest competition is usually a lower-priced generic with the same strength and dosage form. Indirect competition includes suppositories, ointments, wipes, protective barriers, and combination products. A new product must therefore create a clear benefit in use, not merely alter the inactive ingredient list.

What commercial opportunities exist for an improved Proctosol-HC formulation?

Premium preservative-free product

A single-use product could command a premium by reducing contamination concerns and improving portability. The best targets are patients with recurrent use, sensitivity to preservatives, or preference for hygienic unit dosing.

Commercial disadvantages include higher packaging costs, increased waste, and potentially lower pharmacy margins. The product would need efficient foil, tube, or applicator manufacturing to maintain contribution margin.

Senior-friendly and low-trauma applicator

Hemorrhoidal disease has a substantial older-adult user base. A rounded, flexible, low-force applicator with clear dose control could support differentiation through usability. Packaging instructions, grip design, and opening force would be important design inputs.

Bioadhesive or longer-residence cream

A longer-residence formulation could reduce leakage and application frequency. The opportunity is strongest if residence time can be linked to symptom relief, patient preference, or reduced application frequency.

Pharmacy and private-label platform

A manufacturer could use the same validated cream base for multiple strengths, package sizes, and retailer brands. A platform strategy can reduce development and scale-up costs. The core manufacturing asset would be the emulsion process, preservative system, filling line, and applicator package.

International licensing

Geographic expansion is more likely to depend on local registration, trademark ownership, manufacturing authorization, and product classification than on U.S. patent rights. Some markets may treat hydrocortisone rectal products as prescription medicines, while others may permit nonprescription sale at specified strengths.

Licensing value would increase if the formulation has one or more of the following:

• Demonstrated stability without refrigeration.
• Regional manufacturing advantage.
• A proprietary applicator.
• Preservative-free packaging.
• Clinical or human-factors data.
• Existing registrations in multiple jurisdictions.

What manufacturing and intellectual-property barriers matter?

The principal manufacturing barriers are process control and packaging compatibility. Hydrocortisone acetate must be uniformly dispersed, and the cream must remain stable through filling, transport, and storage.

Key technical controls include:

• Active particle-size distribution.
• Homogenization and mixing parameters.
• Emulsion droplet-size distribution.
• Fill-weight accuracy.
• Content uniformity.
• Viscosity and yield stress.
• Preservative effectiveness.
• Tube and applicator compatibility.
• Extractables and leachables.
• In-use stability.

The most defensible IP estate would combine formulation claims, process claims, packaging claims, and device claims. A single narrow composition claim is less durable because competitors may design around it by changing polymer levels, preservative choice, oil-phase composition, or package format.

What litigation, Paragraph IV, and settlement risks exist?

Paragraph IV risk is generally tied to active Orange Book-listed patents for the relevant reference product. A conventional generic applicant could challenge listed formulation or method-of-use patents, while a differentiated product may avoid some claims through a different vehicle or a section viii labeling carve-out.

Potential dispute areas include:

• Whether the proposed cream has the same dosage form and route.
• Whether the formulation infringes a defined excipient range.
• Whether a process claim is practiced during manufacture.
• Whether a method-of-use claim requires restricted labeling.
• Whether the applicant’s formulation is therapeutically equivalent.
• Whether an applicator constitutes a separate protected device.

Settlement agreements could include delayed launch, licensed entry, authorized-generic arrangements, or restrictions on specific indications. Their value depends on the strength of the asserted patents, remaining patent term, expected litigation cost, and market share at risk. No reliable commercial conclusion should be drawn from a patent challenge without reviewing the complaint, patents, Orange Book listing, and settlement terms.

How should an excipient-focused development program be prioritized?

A practical development sequence is:

1. Establish a baseline hydrocortisone acetate cream matching the performance of the existing market product.
2. Screen preservative-free and low-irritancy systems.
3. Evaluate single-use and airless packaging.
4. Test rheology, extrusion force, spreadability, leakage, and residue.
5. Assess bioadhesive polymers only after patient-use requirements are defined.
6. Develop an applicator that supports dose control and low-trauma administration.
7. File composition, process, packaging, and device claims around the best-performing system.
8. Select the regulatory pathway based on the degree of formulation and delivery change.
9. Build a private-label or licensed-manufacturing platform to improve volume economics.

The highest near-term commercial potential is a preservative-conscious, single-use or low-contamination product with an easy-to-use applicator. A controlled-release or strongly bioadhesive product offers greater patent potential but carries materially higher clinical and regulatory risk.

Key Takeaways

• Proctosol-HC is a 2.5% hydrocortisone acetate rectal cream with a conventional emulsion-based excipient system.
• The active ingredient provides limited exclusivity value; commercial differentiation must come from formulation, packaging, or delivery.
• The strongest excipient opportunities involve preservative reduction, single-use dosing, bioadhesion, and improved patient handling.
• Routine substitution of fatty alcohols, emollients, or preservatives is unlikely to create strong patent protection.
• Formulation, process, applicator, and packaging claims should be developed as an integrated IP estate.
• Paragraph IV risk depends on current Orange Book listings for the relevant reference product, not on the Proctosol-HC brand name alone.
• Biosimilar risk does not apply.
• The best near-term opportunity is a premium, low-contamination product supported by a differentiated applicator and validated usability data.

FAQs

Can a preservative-free Proctosol-HC cream be commercially differentiated?

Yes. A preservative-free product could target patients concerned about irritation or repeated contamination. The commercial model is strongest when single-use packaging or an airless system supports the microbiological claim.

Is propylene glycol a major formulation risk in rectal hydrocortisone cream?

Propylene glycol can contribute to hydration and solvent performance, but concentration and patient tolerance must be controlled because sensitive tissue may react to certain excipients. A lower-irritancy formulation could use a different humectant or reduce the solvent load.

Can a hydrocortisone acetate rectal cream obtain formulation patent protection?

Yes, but protection is more credible when the formulation has defined composition ranges tied to measurable performance, such as improved residence time, reduced extrusion force, enhanced stability, or lower irritation.

Would a new applicator make the product a combination product?

Potentially. FDA classification depends on the relationship between the drug and delivery device and the product’s intended use. A separately protected applicator can also create commercial differentiation even when the cream itself is conventional.

Is an OTC conversion a realistic opportunity for Proctosol-HC?

It may be possible for a lower-strength or otherwise qualifying hydrocortisone product, but the sponsor would need to satisfy applicable OTC requirements, labeling conditions, safety expectations, and product-specific regulatory standards. A prescription-strength rectal product cannot be assumed to qualify automatically.

References

1. DailyMed. (n.d.). Proctosol-HC: Hydrocortisone acetate 2.5% rectal cream prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database
3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
4. International Council for Harmonisation. (2003). Q6A: Specifications: Test procedures and acceptance criteria for new drug substances and new drug products.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm